A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax. The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinas...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Leukemia
Main Authors: Phillips, Darren C., Jin, Sha, Gregory, Gareth P., Zhang, Qi, Xue, John, Zhao, Xiaoxian, Chen, Jun, Tong, Yunsong, Zhang, Haichao, Smith, Morey, Tahir, Stephen K., Clark, Rick F., Penning, Thomas D., Devlin, Jennifer R., Shortt, Jake, Hsi, Eric D., Albert, Daniel H., Konopleva, Marina, Johnstone, Ricky W., Leverson, Joel D., Souers, Andrew J.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7266741/
https://ncbi.nlm.nih.gov/pubmed/31827241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0652-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares